Unpacking the Implications of the Negotiated Drug List, Part 2
Summary
In Part 2 of our video series on the negotiated drug list, Avalere experts discuss topics including effectiveness measures that will inform CMS’s maximum fair price determinations, evidence generation strategies for manufacturers with products that have been selected for negotiation, or that are eligible for selection in the future, and CMS’s definition of therapeutic alternatives.In case you missed it, watch Unpacking the Implications of the Negotiated Drug List, Part 1.
Sign up to view Part 2.
2025: Opportunity Through Uncertainty
Sign Up for Our 2025 Healthcare Industry Outlook Webinar
Register Now
January 23, 11 AM ET
Learn MoreServices
From beginning to end, our team synergy
produces measurable results. Let's work together.
produces measurable results. Let's work together.
